The whole-genome landscape of medulloblastoma subtypes
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
Current therapies for medulloblastoma, a highly malignant childhood brain tumour, impose debilitating effects on the developing child, and highlight the need for molecularly targeted treatments with reduced toxicity. Previous studies have been unable to identify the full spectrum of driver genes and molecular processes that operate in medulloblastoma subgroups. Here we analyse the somatic landscape across 491 sequenced medulloblastoma samples and the molecular heterogeneity among 1,256 epigenetically analysed cases, and identify subgroup-specific driver alterations that include previously undiscovered actionable targets. Driver mutations were confidently assigned to most patients belonging to Group 3 and Group 4 medulloblastoma subgroups, greatly enhancing previous knowledge. New molecular subtypes were differentially enriched for specific driver events, including hotspot in-frame insertions that target KBTBD4 and ‘enhancer hijacking’ events that activate PRDM6. Thus, the application of integrative genomics to an extensive cohort of clinical samples derived from a single childhood cancer entity revealed a series of cancer genes and biologically relevant subtype diversity that represent attractive therapeutic targets for the treatment of patients with medulloblastoma. Genomic analysis of 491 medulloblastoma samples, including methylation profiling of 1,256 cases, effectively assigns candidate drivers to most tumours across all molecular subgroups. Medulloblastomas are highly malignant brain tumours that develop during childhood. Paul Northcott and colleagues analysed the whole-genome sequences of 491 medulloblastomas in order to characterize the genomic landscape across tumours and identify new drivers and mutational signatures. Their integrative genomic analyses, including methylation profiling of 1,256 medulloblastomas, identifies subgroup-specific driver mutations and suggests additional tumour subtypes. The authors assign driver mutations to a high proportion of the less well characterized Group 3 and Group 4, which together contribute to more than 60% of all medulloblastomas.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The overlap observed between the G3 and G4 tumors with respect to MYC amplification supports the working hypothesis that these medulloblastomas are not easily separable in part because they originate from a shared cerebellar progenitor cell pool, with each group arising from arrest at different points along a developmental stage continuum (8, 23).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Methylation array–based classification studies have categorized the G3/G4-2, G3/G4-3, and G3/G4-4 molecular subgroups as G3; the G3/G4-1, G3/G4-5, and G3/G4-6 subgroups as a mix of G3 and G4; and the G3/G4-7 and G3/G4-8 subgroups as primarily G4 (8).”
From The Medulloblastoma Meta-Analysis Portal Enables Integrative Exploration of Clinical and Genomic Data from Patients (2025) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041 · cited 2×
“T 0) 42 .”
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
BEDTools: a flexible suite of utilities for comparing genomic features
Quinlan, A. R., & Hall, I. M. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq033 · Cited by 27,437
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., Ohgaki, H., Wiestler, O. D., Kleihues, P., & Ellison, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1545-1 · Cited by 15,657 · cited 1×
“The relatively recent recognition of consensus MB subgroups has rapidly changed the way MB is studied in the research setting and how it is diagnosed and treated in the clinic 39 .”
The 2007 WHO Classification of Tumours of the Central Nervous System
Louis, D. N., Ohgaki, H., Wiestler, O. D., Cavenee, W. K., Burger, P. C., Jouvet, A., Scheithauer, B. W., & Kleihues, P. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0243-4 · Cited by 15,397
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
Wang, K., Li, M., & Hakonarson, H. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq603 · Cited by 14,621 · cited 1×
“The functional effect of the mutations was annotated using Annovar 43 and the variants were assessed for their confidence and split into somatic and non-somatic calls.”
Principal components analysis corrects for stratification in genome-wide association studies
Price, A. L., Patterson, N. J., Plenge, R. M., Weinblatt, M. E., Shadick, N. A., & Reich, D. (2006) · Nature Genetics · doi:10.1038/ng1847 · Cited by 10,248
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“…previously detected in MB 16 and has been linked with underlying BRCA1 and BRCA2 mutations in breast, aggressive prostate, and pancreatic cancers 16,17 , was unexpectedly observed in most of the patients with Group 3 and Group 4 MB, and a subset of patients with SHH MB. Additional…”
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
dbSNP: the NCBI database of genetic variation
Sherry, S. T. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.1.308 · Cited by 7,502
Cited by
Items 501–600 of 998
Schubert, N. A., Lowery, C. D., Bergthold, G., Köster, J., Eleveld, T. F., Rodríguez, A. I. E., Jones, D., Vassal, G., Stancato, L. F., Pfister, S. M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.01.027 · Cited by 12
Self-citationRen, Y., Zhang, Y., Wang, D., Liu, F., Fu, Y., Xiang, S., Su, L., Li, J., Dai, H., & Huang, B. (2020) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2020.02.003 · Cited by 13
“For variant calling of ctDNA samples, we used an algorithm based on samtools mpileup [28] developed in-house to detect somatic SNVs and indels [29,30].”
MethodWerbowetski‐Ogilvie, T. E. (2021) · FEBS Journal · doi:10.1111/febs.15817 · Cited by 16
SEOM clinical guideline for management of adult medulloblastoma (2020)
Luque, R., Benavides, M., del Barco, S., Egaña, L., García-Gómez, J., Martinez‐García, M., Pérez‐Segura, P., Pineda, E., Sepúlveda-Sánchez, J. M., & Vieito, M. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02581-1 · Cited by 12
Lettieri, A., Oleari, R., Paganoni, A. J. J., Gervasini, C., Massa, V., Fantin, A., & Cariboni, A. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.638674 · Cited by 17
Deogharkar, A., Singh, S. V., Bharambe, H. S., Paul, R., Moiyadi, A. V., Goel, A. H., Shetty, P. M., Epari, S., Gupta, T., Jalali, R., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab134 · Cited by 12
Three‐dimensional genome architecture in health and disease
Ouimette, J., Rougeulle, C., & Veitia, R. A. (2018) · Clinical Genetics · doi:10.1111/cge.13219 · Cited by 15
Islam, M. R., Abdulrazak, L. F., Alam, M. K., Paul, B. K., Ahmed, K., Bui, F. M., & Moni, M. A. (2022) · BioMed Research International · doi:10.1155/2022/1776082 · Cited by 11
“Molecular subgroups of MB have been displayed to exhibit characteristic genomic landscapes, and these are connected with several risk factors [3, 4].”
BackgroundRetractedBúzová, D., Fröhlich, J., Zapletalová, D., Raffaele, M., Re, O. L., Tsoneva, D. K., Štěrba, J., Červený, J., & Vinciguerra, M. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1254699 · Cited by 12
“In the long term, the identi fi cation and monitoring of molecular changes would likely be critical for the clinical management of pediatric tumours, overcoming the limitations of magnetic resonance imaging (MRI) and of histology (Northcott et al., 2017; Salloum et al., 2017).”
BackgroundMYC overexpression and SMARCA4 loss cooperate to drive medulloblastoma formation in mice
Göbel, C., Godbole, S., Schoof, M., Holdhof, D., Kresbach, C., Loose, C., Neumann, J. E., & Schüller, U. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01654-2 · Cited by 16
“MYC and SMARCA can also be concurrently altered as detected in around 1–6% of Group 3 MB [17, 29, 44, 55].”
BackgroundCrotty, E. E., Paulson, V., Ronsley, R. J., Vitanza, N. A., Lee, A. S., Hauptman, J. S., Goldstein, H. E., Lockwood, C. M., Leary, S. E. S., & Cole, B. (2024) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdae126 · Cited by 15
NeKo: A tool for automatic network construction from prior knowledge
Ruscone, M., Tsirvouli, E., Checcoli, A., Türei, D., Barillot, E., Sáez-Rodríguez, J., Martignetti, L., Flobak, Å., & Calzone, L. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1013300 · Cited by 18
“The network construction process starts with collecting genes/proteins of interest from major publications that focus on medulloblastoma [22].”
G9a/EHMT2 is a Potential Prognostic Biomarker and Molecular Target in SHH Medulloblastoma
Souza, B. K., Freire, N. H., Jaeger, M. D. C., de Farias, C. B., Brunetto, A. L., Brunetto, A. T., & Roesler, R. (2022) · NeuroMolecular Medicine · doi:10.1007/s12017-022-08702-5 · Cited by 11
Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas
Wang, Y., Wu, H., Ren, Y., Lv, S., Ji, C., Xiang, D., Zhang, M., Lu, H., Fu, W., Liu, Q., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00890-7 · Cited by 11
“Thus, current molecular classifications of MBs have potent clinical relevance as each subgroup or subtype manifests different clinical features and outcomes.(22,23) However, much is desired for a better understanding of the molecular heterogeneity of MBs for refined molecular subclassification.”
BackgroundSelf-citationDanilenko, M., Zaka, M., Keeling, C., Crosier, S., Lyman, S., Finetti, M. A., Williamson, D., Hussain, R., Coxhead, J., Zhou, P., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02464-x · Cited by 12
“Mutational analysis interrogated 192 genes previously either reported as frequently mutated driver genes in medulloblastoma or recognised to be acquired in relapsed disease [25, 29, 30, 38].”
BackgroundLee, B., Katsushima, K., Pokhrel, R., Yuan, M., Stapleton, S. L., Jallo, G. I., Wechsler‐Reya, R. J., Eberhart, C. G., Ray, A., & Perera, R. J. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac120 · Cited by 11
Towards Precision Oncology: The Role of Smoothened and Its Variants in Cancer
Nicheperovich, A., & Townsend‐Nicholson, A. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101648 · Cited by 12
“Figure 6b confirms that the 7TM domain experiences a higher mutational pressure in the context of cancer, with the exception of TM2.”
BackgroundGroup-specific cellular metabolism in Medulloblastoma
Funke, V. L. E., Walter, C., Melcher, V., Wei, L., Sandmann, S., Hotfilder, M., Varghese, J., Jäger, N., Kool, M., Jones, D., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04211-6 · Cited by 11
Self-citationEYA2 tyrosine phosphatase inhibition reduces MYC and prevents medulloblastoma progression
Wolin, A. R., Vincent, M. Y., Hotz, T. J., Purdy, S. C., Rosenbaum, S. R., Hughes, C. J., Hsu, J. Y., Oliphant, M. U. J., Armstrong, B. A., Wessells, V. M., et al. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noad128 · Cited by 17
Zeuner, S., Vollmer, J., Sigaud, R., Oppermann, S., Peterziel, H., ElHarouni, D., Oehme, I., Witt, O., Milde, T., & Ecker, J. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04526-w · Cited by 11
“Primary MB sample mRNA expression data was derived from a public MB gene expression data set (R2 internal identifier: ps_avgpres_mb500affym223_u133p2 [3]), protein expression data was derived from [29].”
BackgroundMethodSelf-citationNiesen, J., Ohli, J., Sedlacik, J., Dührsen, L., Hellwig, M., Spohn, M., Holsten, T., & Schüller, U. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.028 · Cited by 14
Wu, K.-S., Ho, D. M., Jou, S., Yu, A. L.-T., Tran, H. M., Liang, M., Chen, H., Lee, Y., Chen, Y., Lin, S., et al. (2020) · Cancers · doi:10.3390/cancers12030653 · Cited by 11
“Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/3/653/s1, Figure S1: Heatmap of top and bottom 20 genes in the three SHH subtype, Figure S2: The subgroup distribution of clinical parameters in the four core MB subgroups, Figure S3: Top 20 highly expressed metastasis-asso…”
BackgroundInfluentialSelf-citationProtein phosphatase 4 promotes Hedgehog signaling through dephosphorylation of Suppressor of fused
Liao, H., Cai, J., Liu, C., Shen, L., Pu, X., Yao, Y., Han, B., Yu, T., Cheng, S. Y., & Yue, S. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-02843-w · Cited by 12
Ma, M., Han, G., Wang, Y., Zhao, Z., Guan, F., & Li, X. (2020) · Aging · doi:10.18632/aging.202239 · Cited by 11
“Medulloblastoma Molecular subgroups (G3), molecular subgroups (G4), molecular subgroups (SHH), molecular subgroups (WNT) Gender (male), metastasis [74], [75], [76], R2 platform”
BackgroundEnhancer rewiring in tumors: an opportunity for therapeutic intervention
Richart, L., Bidard, F., & Margueron, R. (2021) · Oncogene · doi:10.1038/s41388-021-01793-7 · Cited by 12
Xu, K., Jiang, X., Gabriel, A. N. A., Li, X., Wang, Y., & Xu, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.737670 · Cited by 13
The origins of medulloblastoma tumours in humans
Phoenix, T. N. (2022) · Nature · doi:10.1038/d41586-022-02951-x · Cited by 16
Domenico, A. D., Pipinikas, C., Maire, R., Bräutigam, K., Simillion, C., Dettmer, M. S., Vassella, E., Thirlwell, C., Perren, A. A., & Marinoni, I. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.08.029785 · Cited by 12
Parra, R., Przybilla, M. J., Simovic-Lorenz, M., Sušak, H., Ratnaparkhe, M., Wong, J. K., Körber, V., Mallm, J., Sill, M., Kolb, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.25.449944 · Cited by 11
“In order to identify transcriptional signatures that are specific to CT tumors, we leveraged existing bulk RNA-seq data resources 25 (n=38 non-CT SHH medulloblastomas and n=8 LFS SHH medulloblastomas with CT, Fig.”
BackgroundSelf-citationKurdi, M. E., Mulla, N., Malibary, H. M., Bamaga, A. K., Fadul, M. M., Faizo, E., Hakamy, S., & Baeesa, S. S. (2023) · World Journal of Clinical Oncology · doi:10.5306/wjco.v14.i3.117 · Cited by 13
Benign and Malignant Tumors of the Pineal Region
Upadhyayula, P. S., Neira, J. A., Miller, M. L., & Bruce, J. N. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-23705-8_6 · Cited by 12
Lee, M. K., Azizgolshani, N., Shapiro, J. A., Nguyen, L., Kolling, F., Zanazzi, G. J., Frost, H. R., & Christensen, B. C. (2024) · Nature Communications · doi:10.1038/s41467-024-47712-8 · Cited by 13
Chen, Z., Chi, G., Balo, T., Chen, X., Montes, B. R., Clifford, S. C., D’Angiolella, V., Szabo, T., Kiss, A., Novak, T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58350-z · Cited by 10
Predisposition of Wingless Subgroup Medulloblastoma for Primary Tumor Hemorrhage
Reisinger, D., Gojo, J., Kasprian, G. J., Haberler, C., Peyrl, A., Azizi, A. A., Mayr, L., Chocholous, M., Kool, M., Czech, T., et al. (2019) · Neurosurgery · doi:10.1093/neuros/nyz148 · Cited by 11
Self-citationChe, X., Qi, X., Xu, Y., Wang, Q., & Wu, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/5561124 · Cited by 12
“Tumor mutational burden (TMB) [23] is an emerging biomarker considered for predicting ICI treatment response.”
BackgroundInfluentialSelf-citationIndividualized discovery of rare cancer drivers in global network context
Petrov, I., & Alexeyenko, A. (2022) · eLife · doi:10.7554/elife.74010 · Cited by 9
Angiogenesis and Lymphangiogenesis in Medulloblastoma Development
Penco-Campillo, M., Pagès, G., & Martial, S. (2023) · Biology · doi:10.3390/biology12071028 · Cited by 10
“In 2017, three independent studies identified several molecular subtypes based on DNA methylation profiling assays: (i) An integrative analysis of 491 tumors from untreated patients subdivided Subgroups 3 and 4 into eight molecularly distinct subtypes (I-VIII) with specific, albeit somehow overlapping, genetic and tra…”
BackgroundCole, B., Lockwood, C. M., Stasi, S. M., Stevens, J., Lee, A., Ojemann, J. G., Ellenbogen, R. G., & Leary, S. E. S. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00151 · Cited by 10
A functional genomics approach to identify pathways of drug resistance in medulloblastoma
Bertrand, K. C., Faria, C. C., Skowron, P., Luck, A. J., Garzia, L., Wu, X., Agnihotri, S., Smith, C. A., Taylor, M. D., Mack, S. C., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0652-8 · Cited by 10
“Medulloblastoma is classified into four demographically, clinically, and molecularly distinct subgroups called WNT, SHH, Group 3 and Group 4 (As reviewed in [19]), and further divided into additional distinct molecular subtypes [3, 14].”
Self-citationWNT-Activated Medulloblastomas With Hybrid Molecular Subtypes
Helgager, J. J., Pytel, P., Vasudevaraja, V., Lee, E. Q., Snuderl, M., Iorgulescu, J. B., & Ligon, K. L. (2020) · JCO Precision Oncology · doi:10.1200/po.19.00332 · Cited by 10
“Recently, however, several patients with medulloblastoma have been reported to harbor combined molecular alterations characteristic of both WNT- and SHH-activated tumors.(4,5) We report 2 additional patients with medulloblastoma with hybrid subclass features, one with WNT/SHH dual-activation tumors and another, striki…”
BackgroundIdentification of Core Genes and Pathways in Medulloblastoma by Integrated Bioinformatics Analysis
Guo, Y., Huang, P., Ning, W., Zhang, H., & Yu, C. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01556-1 · Cited by 10
The mutREAD method detects mutational signatures from low quantities of cancer DNA
Perner, J., Abbas, S., Nowicki-Osuch, K., Devonshire, G., Eldridge, M., Tavaré, S., & Fitzgerald, R. C. (2020) · Nature Communications · doi:10.1038/s41467-020-16974-3 · Cited by 10
Shiraishi, R., & Kawauchi, D. (2021) · Cancer Science · doi:10.1111/cas.14990 · Cited by 14
The Current Landscape of Targeted Clinical Trials in Non-WNT/Non-SHH Medulloblastoma
Ghasemi, D. R., Fleischhack, G., Milde, T., & Pajtler, K. W. (2022) · Cancers · doi:10.3390/cancers14030679 · Cited by 13
“Within the SHH group, which comprises about 25–30% of all cases, mutations and copy number variations (CNVs) of SHH-pathway members (PTCH1, SUFU, SMO, GLI1/2, MYCN) and alterations of TP53 and TERT are characteristic genetic hallmarks [4,8,10,12,13,17].”
BackgroundInfluentialSelf-citationA Review of Complex Systems Approaches to Cancer Networks
Uthamacumaran, A. (2020) · Complex Systems · doi:10.25088/complexsystems.29.4.779 · Cited by 11
“Single-cell transcriptomics-based cell lineage reconstruction revealed four distinct targetable clusters in pediatric medulloblastoma (Northcott et al., 2017 [36]; Vladoiu et al., 2019 [37]).”
BackgroundChildhood Cerebellar Tumors Mirror Conserved Fetal Transcriptional ProgramsPreprint
Vladoiu, M. C., El-Hamamy, I., Donovan, L., Farooq, H., Holgado, B., Ramaswamy, V., Mack, S. C., Lee, J. J., Kumar, S. A., Przelicki, D., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/350280 · Cited by 11
Self-citationThe tumor suppressor CREBBP and the oncogene MYCN cooperate to induce malignant brain tumors in mice
Schoof, M., Epplen, G. D., Walter, C., Ballast, A., Holdhof, D., Göbel, C., Neyazi, S., Varghese, J., Albert, T., Kerl, K., et al. (2023) · Oncogenesis · doi:10.1038/s41389-023-00481-3 · Cited by 10
“Mutations in genes involved in histone acetylation – including CREBBP – are overrepresented in Sonic hedgehog (SHH)-activated medulloblastoma [4, 5].”
BackgroundEnhancers dysfunction in the 3D genome of cancer cells
Chiara, G. D., Jiménez, C., Virdi, M., Crosetto, N., & Bienko, M. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1303862 · Cited by 9
“…as medulloblastoma, pancreatic and thyroid cancers, multiple myeloma, mantle cell lymphoma, and several leukemias, causing dysregulation/activation of several proto-oncogenes (Gröschel et al., 2014; Bandopadhayay et al., 2016; Northcott et al., 2017; Ren et al., 2021; Rico et al., 2022) (Table 1).”
BackgroundQi, L., Baxter, P. A., Kogiso, M., Zhang, H., Braun, F., Lindsay, H., Zhao, S., Xiao, S., Abdallah, A. S., Suárez, M., et al. (2024) · Cancers · doi:10.3390/cancers16091716 · Cited by 10
Chen, F., Zhang, Y., Shen, L., & Creighton, C. J. (2024) · Nature Communications · doi:10.1038/s41467-024-51276-y · Cited by 13
Sonic hedgehog signalling pathway in CNS tumours: its role and therapeutic implications
Awuah, W. A., Ben-Jaafar, A., Kong, J. S. H., Mannan, K. M., Sanker, V., Rosenke, S., Boye, A. N. A., Nkrumah-Boateng, P. A., Poornaselvan, J., Shah, M. H., et al. (2024) · Molecular Brain · doi:10.1186/s13041-024-01155-w · Cited by 12
Kim, D. T., Uloho-Okundaye, M., Frederico, S. C., Guru, S., Kim, M. J., & Chang, S. D. (2025) · Brain Sciences · doi:10.3390/brainsci15080896 · Cited by 13
“The majority of Wnt MBs are characterized by a mutation in the CTNNB1 gene, typically at exon 3, resulting in a lack of phosphorylation-driven degradation of β -catenin within the nucleus, leading to the constitutive activation of the Wnt signaling pathway [6].”
Veo, B. L., Wang, D., DeSisto, J. A., Pierce, A. M., Brunt, B., Bompada, P., Donson, A. M., Goodspeed, A. E., Smart, K., Foreman, N. K., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-65466-9 · Cited by 16
Loss of AMPKα2 Impairs Hedgehog-Driven Medulloblastoma Tumorigenesis
Zhang, H., Kuick, R. D., Park, S. S., Peabody, C., Yoon, J. G., Fernández, E. C., Wang, J., Thomas, D. G., Viollet, B., Inoki, K., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113287 · Cited by 8
“We analyzed the publicly available copy number data for medulloblastoma samples estimated from short-read DNA sequencing [5].”
MethodInfluentialChe, X., Qi, X., Xu, Y., Wang, Q., & Wu, G. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6613151 · Cited by 11
Self-citationKloth, K., Obrecht, D., Sturm, D., Pietsch, T., Warmuth‐Metz, M., Bison, B., Mynarek, M., & Rutkowski, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756025 · Cited by 9
“They are further characterized by their varying origins, molecular drivers, demographics and clinical outcomes (16, 17).”
BackgroundHo, V. K. Y., Gijtenbeek, A., Wagemakers, M., Taal, W., Linde, M. E. V., Swaak‐Kragten, A. T., Kurt, E., van der Weide, H. L., Wesseling, P., Vos, F. D., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac062 · Cited by 9
Paediatric brain tumours in Singapore: A 15-year epidemiological and outcome study
Liu, S. J., Aw, M. Y. N., Lim, M. J. R., Seow, W. T., Low, D. C. Y., Kimpo, M. S., Tan, E. E. K., Yeo, T. T., Low, S. Y. Y., & Nga, V. D. W. (2022) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2022.05.006 · Cited by 9
Protocol for the Tessa Jowell BRAIN MATRIX Platform Study
Watts, C., Savage, J., Patel, A. S., Mant, R., Wykes, V., Pohl, U., Bulbeck, H., Apps, J. R., Sharpe, R., Thompson, G., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-067123 · Cited by 11
Review of the impact of molecular analysis on the therapy of medulloblastoma
Sarvode, S., & Gajjar, A. J. (2023) · Pediatric Hematology Oncology Journal · doi:10.1016/j.phoj.2023.05.001 · Cited by 9
Self-citationMYC Promotes Aggressive Growth and Metastasis of a WNT-Medulloblastoma Mouse Model
Hartley, R., & Phoenix, T. N. (2023) · Developmental Neuroscience · doi:10.1159/000533270 · Cited by 9
“Group 3-MB (GRP3-MB), commonly classi fi ed as high-risk, is frequently metastatic and contains genomic alterations, resulting in increased MYC expression [8 – 10 , 19].”
BackgroundRecent Advances in Understanding the Role of Autophagy in Paediatric Brain Tumours
Gatto, F., Milletti, G., Carai, A., Mastronuzzi, A., & Nazio, F. (2021) · Diagnostics · doi:10.3390/diagnostics11030481 · Cited by 9
“Similar distribution in both subgroups was detected also for structural variants leading to the aberrant and mutually exclusive activation of growth factor independent 1 family proto-oncogenes (GFI1 or GFI1B) [62].”
BackgroundTen-eleven translocation protein 1 modulates medulloblastoma progression
Kim, H., Kang, Y., Li, Y., Chen, L., Lin, L., Johnson, N. D., Zhu, D., Robinson, M. H., McSwain, L., Barwick, B. G., et al. (2021) · Genome biology · doi:10.1186/s13059-021-02352-9 · Cited by 10
“In addition, no focal amplification/deletion of enzymes involved in cytosine dynamics has been observed in previous studies [32].”
ResultIdentification of pseudolaric acid B as a novel Hedgehog pathway inhibitor in medulloblastoma
Wei, S.-F., He, D., Zhang, S., Lu, Y., Ye, X., Fan, X., Wang, H., Wang, Q., & Liu, Y. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114593 · Cited by 9
Self-citationWorld Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology
Sulman, E. P., & Eisenstat, D. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659800 · Cited by 13
“With the advent and subsequent implementation of platforms such as whole genome sequencing (2), single cell nucleic acid sequencing (3–7), nanostring technology (8, 9) and DNA methylation (10–12) profiling, some diagnostic categories have been replaced, such as the former primitive neuroepithelial tumor (PNET)grouping…”
MethodOverview and recent advances in the targeting of medulloblastoma cancer stem cells
Paul, M. R., & Zage, P. E. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1932472 · Cited by 11
Role of mammalian long non-coding RNAs in normal and neuro oncological disorders
Singh, N. (2021) · Genomics · doi:10.1016/j.ygeno.2021.07.015 · Cited by 9
The transcriptional stress response and its implications in cancer treatment
Cruz-Ruiz, S., Urióstegui-Arcos, M., & Zurita, M. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188620 · Cited by 9
Krausert, S., Brabetz, S., Mack, N. L., Schmitt-Hoffner, F., Schwalm, B., Peterziel, H., Mangang, A., Holland‐Letz, T., Sieber, L., Korshunov, A., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac026 · Cited by 17
Self-citationSmit, M. J., Martini, T. E. I., Armandari, I., Bočkaj, I., Zomerman, W. W., Magalhães, E. S. D. C., Siragna, Z., Boer, T. M.-D., Scherpen, F. J. G., Schoots, M. H., et al. (2022) · Journal of Cell Science · doi:10.1242/jcs.258608 · Cited by 11
Li, M., Han, Y., Wang, C., Kang, W., Jiang, W., Zhang, L., & Tang, Y. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02506-y · Cited by 10
Valinciute, G., Ecker, J., Selt, F., Hielscher, T., Sigaud, R., Ridinger, J., Thatikonda, V., Gatzweiler, C., Robinson, S., Talbot, J., et al. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04319-1 · Cited by 11
Self-citationSignaling pathway deregulation and molecular alterations across pediatric medulloblastomas
Lhermitte, B., Blandin, A.-F., Coca, A. H., Guérin, É., Durand, A., & Entz‐Werlé, N. (2021) · Neurochirurgie · doi:10.1016/j.neuchi.2018.01.003 · Cited by 11
2021 World Health Organization Classification of Brain Tumors
Meredith, D. M., & Pisapia, D. J. (2023) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001355 · Cited by 10
Wei, G., Zhang, X., Liu, S., Hou, W., & Dai, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-62256-z · Cited by 10
CoREST in pieces: Dismantling the CoREST complex for cancer therapy and beyond
Ismail, H., Chagraoui, J., & Sauvageau, G. (2025) · Science Advances · doi:10.1126/sciadv.ads6556 · Cited by 9
Smith, K. S., Dhanda, S. K., Billups, C. A., Sioson, E., Lu, C., Peraza, A. Z., Gangwani, K., Li, Y., Li, Q., Lin, T., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf250 · Cited by 11
Self-citationDegrons and degradation signals beyond short linear motifs
Wang, B., & Zheng, N. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-02056-2 · Cited by 11
“Mutations in the CRL3 adaptor KBTBD4 were identified in patients with medulloblastoma and occur in a hotspot on the surface of the E3 ligase 109,110 .”
Tian, S., Sudmeier, L. J., Zhang, C., Madden, N. A., Buchwald, Z. S., Shu, H. G., Curran, W. J., Eaton, B. R., & Esiashvili, N. (2019) · Pediatric Blood & Cancer · doi:10.1002/pbc.28027 · Cited by 8
A systematic analysis of genetic interactions and their underlying biology in childhood cancer
Daub, J. T., Amini, S., Kersjes, D. J. E., Ma, X., Jäger, N., Zhang, J., Pfister, S. M., Holstege, F. C. P., & Kemmeren, P. (2021) · Communications Biology · doi:10.1038/s42003-021-02647-4 · Cited by 10
Self-citationIdentification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma
Alaña, L., Nunes‐Xavier, C. E., Zaldumbide, L., Martín‐Guerrero, I., Mosteiro, L., Alba‐Pavón, P., Villate, O., García‐Obregón, S., González-García, H., Herraiz, R., et al. (2022) · Cancers · doi:10.3390/cancers14020421 · Cited by 8
“New molecular subtypes were differentially enriched for specific drivers as KBTBD4 and PRDM6 in these subgroups [12].”
BackgroundKorshunov, A., Okonechnikov, K., Schrimpf, D., Tonn, S., Mynarek, M., Köster, J., Sievers, P., Milde, T., Sahm, F., Jones, D., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02575-z · Cited by 9
“In line with previous reports [17, 25], unfavorable (SGS MB II and III), intermediate (SGS MB IV and V), and standard/low-risk (SGS MB VI, VII, and VIII) survival cohorts were identified.”
BackgroundMethodResultSelf-citationNtenti, C., Lallas, K., & Papazisis, G. (2023) · Diagnostics · doi:10.3390/diagnostics13111915 · Cited by 10
“The above-mentioned markers are used to identify WNT MBs, but 1 in 10 MBs can be missed [71].”
BackgroundA sterol analog inhibits hedgehog pathway by blocking cholesterylation of smoothened
Liu, Y., He, L., Sun, M., Luo, W.-J., Lin, Z., Qiu, Z.-P., Zhang, Y., Hu, A., Luo, J., Qiu, W., et al. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.002 · Cited by 8
Self-citationThe pivotal role of irradiation‐induced apoptosis in the pathogenesis and therapy of medulloblastoma
Richard, S. A. (2024) · Cancer Reports · doi:10.1002/cnr2.2048 · Cited by 7
“25 Furthermore, abnormal MYC augmentation have been observed in about 17% of patients with group 3 MB and this reflects an essential feature of this subgroup.”
BackgroundPediatric neuro-oncology: Highlights of the last quarter-century
Power, P., Straehla, J. P., Fangusaro, J., Bandopadhayay, P., & Manoharan, N. (2024) · Neoplasia · doi:10.1016/j.neo.2024.101098 · Cited by 10
“Large-scale molecular analyses subsequently confirmed the biologic and clinical heterogeneity of these subgroups, and have further delineated 12 subtypes; the clinical implications of these subtypes are an area of active investigation [20,21].”
Targeting protein synthesis pathways in MYC-amplified medulloblastoma
Kumar, D., Kanchan, R. K., & Chaturvedi, N. K. (2025) · Discover Oncology · doi:10.1007/s12672-025-01761-7 · Cited by 10
Inferred developmental origins of brain tumors from single-cell RNA-sequencing data
Wang, S., Curry, R. N., McDonald, M. F., Koh, H. Y., Erickson, A. W., Kleinman, C. L., Taylor, M. D., Rao, G., Deneen, B., Harmanci, A. O., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf016 · Cited by 11
Self-citationRobson, J. P., Remke, M., Kool, M., Julian, E., Korshunov, A., Pfister, S. M., Osborne, G. W., Taylor, M. D., Wainwright, B. J., & Reynolds, B. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210665 · Cited by 9
Self-citationBrain and Spinal Cord Tumors in Children
Tailor, J. K., & Jackson, E. M. (2021) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2021.04.007 · Cited by 8
Rea, J. N., Carissimo, A., Trisciuoglio, D., Illi, B., Picard, D. J., Remke, M., Laneve, P., & Caffarelli, E. (2021) · Cancers · doi:10.3390/cancers13153853 · Cited by 8
Long non-coding RNAs as a predictive markers of group 3 medulloblastomas
Mutlu, M. B., Tekin, Ç., Aksoy, S. A., Taşkapılıoğlu, M. Ö., Kaya, S., Balçın, R. N., Ocak, P. E., Kocaelı, H., Bekâr, A., Tolunay, Ş., et al. (2021) · Neurological Research · doi:10.1080/01616412.2021.1975223 · Cited by 8
“In addition, the amplification of OTX-2, SMARCA4 mutation, and enhancer activation of GFI1 and GFI1B are repetitive genetic changes [21].”
BackgroundChagas, P. S., de Sousa, G. R., Veronez, L. C., Martins-da-Silva, A., Corrêa, C. A. P., Cruzeiro, G. A. V., Nagano, L. F. P., Queiróz, R. G. D. P., Marie, S. K. N., Brandalise, S. R., et al. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01942-3 · Cited by 11
Rocha, C., & Prinos, P. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.809917 · Cited by 8
Sonic hedgehog signaling: Alternative splicing and pathogenic role in medulloblastoma
Qu, M., He, Q., Luo, J., Shen, T., Gao, R., Xu, Y., Xu, C., Barkat, M. Q., Zeng, L., & Wu, X. (2022) · Genes & Diseases · doi:10.1016/j.gendis.2022.10.014 · Cited by 9
Self-citationWu, X., Wang, A., Wang, M., Peng, Y., Chen, Y., Li, J., Liu, Z., Lu, H., Zhou, J., Peng, L., et al. (2023) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02978-5 · Cited by 8
Self-citationde Ståhl, T. D., Shamikh, A., Mayrhofer, M., Juhos, S., Basmaci, E., Prochazka, G., Garcia, M., Somarajan, P. R., Zielinska-Chomej, K., Illies, C., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04178-4 · Cited by 11
“We focused on detecting mutations in genes reported to be involved in cancer, including cancer census genes (Cosmic v90) and genes commonly altered in pediatric tumors identified in previous studies [15, 30, 31, 36].”
BackgroundInfluentialMalignant Brain Tumours in Children : Present and Future Perspectives
Rutka, J. T. (2018) · Journal of Korean Neurosurgical Society · doi:10.3340/jkns.2018.0044 · Cited by 8
Gaviani, P., Simonetti, G., Rudà, R., Franchino, F., Lombardi, G., Possanzini, M., Squintu, S., Villani, V., Teriaca, M. A., Cavallieri, F., et al. (2020) · Neurological Sciences · doi:10.1007/s10072-020-04556-6 · Cited by 8
“In adults, group 3 does not virtually exist [20, 21].”
BackgroundData-driven approaches to advance research and clinical care for pediatric cancer
Gout, A. M., Arunachalam, S., Finkelstein, D., & Zhang, J. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188571 · Cited by 10
Self-citation
Metadata
- Authors
- Northcott, P. A., Buchhalter, I., Morrissy, A. S., Hovestadt, V., Weischenfeldt, J., Ehrenberger, T., Gröbner, S., Segura-Wang, M., Zichner, T., Rudneva, V. A., Warnatz, H.-J., Sidiropoulos, N., Phillips, A. H., Schumacher, S., Kleinheinz, K., Waszak, S. M., Erkek, S., Jones, D. T. W., Worst, B. C., Kool, M., Zapatka, M., Jäger, N., Chavez, L., Hutter, B., Bieg, M., Paramasivam, N., Heinold, M., Gu, Z., Ishaque, N., Jäger-Schmidt, C., Imbusch, C. D., Jugold, A., Hübschmann, D., Risch, T., Amstislavskiy, V., Gonzalez, F. G. R., Weber, U. D., Wolf, S., Robinson, G. W., Zhou, X., Wu, G., Finkelstein, D., Liu, Y., Cavalli, F. M. G., Luu, B., Ramaswamy, V., Wu, X., Koster, J., Ryzhova, M., Cho, Y.-J., Pomeroy, S. L., Herold-Mende, C., Schuhmann, M., Ebinger, M., Liau, L. M., Mora, J., McLendon, R. E., Jabado, N., Kumabe, T., Chuah, E., Ma, Y., Moore, R. A., Mungall, A. J., Mungall, K. L., Thiessen, N., Tse, K., Wong, T., Jones, S. J. M., Witt, O., Milde, T., Von Deimling, A., Capper, D., Korshunov, A., Yaspo, M.-L., Kriwacki, R., Gajjar, A., Zhang, J., Beroukhim, R., Fraenkel, E., Korbel, J. O., Brors, B., Schlesner, M., Eils, R., Marra, M. A., Pfister, S. M., Taylor, M. D., & Lichter, P.
- Affiliations
- St. Jude Children's Research Hospital (US)
- German Cancer Research Center (DE)
- Hospital for Sick Children (CA)
- University of Copenhagen (DK)
- Massachusetts Institute of Technology (US)
- European Molecular Biology Laboratory (DE)
- Max Planck Institute for Molecular Genetics (DE)
- Broad Institute (US)
- Burdenko Neurosurgery Institute (RU)
- Oregon Health & Science University (US)
- Boston Children's Hospital (US)
- Universitätsklinikum Tübingen (DE)
- University Children's Hospital Tübingen (DE)
- University of California, Los Angeles (US)
- Hospital Sant Joan de Déu Barcelona (ES)
- Duke University (US)
- McGill University (CA)
- Kitasato University Hospital (JP)
- BC Cancer Agency (CA)
- University Hospital Heidelberg (DE)
- Corresponding author
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- ORCID
- Northcott, Paul A.
- Buchhalter, Ivo
- Morrissy, A. Sorana
- Hovestadt, Volker
- Weischenfeldt, Joachim
- Zichner, Thomas
- Rudneva, Vasilisa A.
- Warnatz, Hans-Jörg
- Sidiropoulos, Nikos
- Phillips, Aaron H.
- Schumacher, Steven
- Kleinheinz, Kortine
- Waszak, Sebastian M.
- Erkek, Serap
- Jones, David T. W.
- Kool, Marcel
- Zapatka, Marc
- Jäger, Natalie
- Hutter, Barbara
- Bieg, Matthias
- Paramasivam, Nagarajan
- Gu, Zuguang
- Ishaque, Naveed
- Imbusch, Charles D.
- Hübschmann, Daniel
- Amstislavskiy, Vyacheslav
- Robinson, Giles W.
- Zhou, Xin
- Wu, Gang
- Finkelstein, David
- Liu, Yanling
- Cavalli, Florence M. G.
- Ramaswamy, Vijay
- Wu, Xiaochong
- Ryzhova, Marina
- Cho, Yoon-Jae
- Pomeroy, Scott L.
- Schuhmann, Martin
- Ebinger, Martin
- Liau, Linda M.
- Mora, Jaume
- McLendon, Roger E.
- Jabado, Nada
- Kumabe, Toshihiro
- Moore, Richard A.
- Mungall, Andrew J.
- Wong, Tina
- Jones, Steven J. M.
- Witt, Olaf
- Milde, Till
- Capper, David
- Korshunov, Andrey
- Yaspo, Marie-Laure
- Kriwacki, Richard
- Gajjar, Amar
- Zhang, Jinghui
- Beroukhim, Rameen
- Fraenkel, Ernest
- Korbel, Jan O.
- Brors, Benedikt
- Schlesner, Matthias
- Eils, Roland
- Marra, Marco A.
- Pfister, Stefan M.
- Taylor, Michael D.
- Lichter, Peter
- Venue
- Nature
- Published
- 2017-07
- Volume
- 547
- Issue
- 7663
- Pages
- 311-317
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5905700
- OpenAlex
- W2737542366
- Cited by
- 1,112
- References
- 66
- Citations by year
- 2026: 63 · 2025: 132 · 2024: 125 · 2023: 154 · 2022: 142 · 2021: 148 · 2020: 120 · 2019: 120 · 2018: 94 · 2017: 12
- FWCI
- 54.51
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 19 d)
- Locations
- Nature (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Max Planck Digital Library (submittedVersion, other-oa)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- MPG.PuRe (Max Planck Society) (submittedVersion, cc-by)
- OPUS (Augsburg University) (submittedVersion, cc-by)
- Funders
- Alexander and Margaret Stewart Trust
- Pediatric Brain Tumor Foundation (R01CA159859)
- Deutsches Krebsforschungszentrum
- Genome Canada (R01CA159859)
- Children's Hospital Foundation
- Ontario Institute for Cancer Research
- American Lebanese Syrian Associated Charities
- Government of Ontario
- Genome British Columbia (R01CA159859)
- Canada Research Chairs
- Brain Tumour Charity (GN-000356)
- Bundesministerium für Bildung und Forschung (01KU1505E, 01KU1201A, 01KU1505A)
- Terry Fox Research Institute (R01CA159859)
- Deutsche Krebshilfe (109252)
- Hospital for Sick Children
- Stichting Kinderen Kankervrij
- BC Cancer Foundation (FDN-143288)
- Brain Tumour Research
- National Institutes of Health
- Heidelberger Zentrum für Personalisierte Onkologie Deutsches Krebsforschungszentrum In Der Helmholtz-Gemeinschaft
- Garron Family Cancer Centre
- National Cancer Institute (R01CA148699, R01CA109467, R01CA159859)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- medulloblastoma, molecular subtypes, driver mutations, somatic mutations, mutational signatures, enhancer hijacking, in-frame insertion, DNA methylation, Group 3 medulloblastoma, Group 4 medulloblastoma, therapeutic target, childhood brain tumours, integrative genomics
- MeSH terms
- Whole Genome Sequencing, Carrier Proteins, DNA Mutational Analysis, Epistasis, Genetic, Humans, Medulloblastoma, Muscle Proteins, Mutation, Oncogenes, Transcription Factors, Cohort Studies, Genome, Human, DNA Methylation, Genomics, Wnt Proteins, Molecular Targeted Therapy, Carcinogenesis, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.